Celea Therapeutics

Private

#Idiopathic Pulmonary Fibrosis #Respiratory #Fibrotic disease #Inflammatory lung disease

Celea Therapeutics is a clinical-stage respiratory therapeutics company spun out of PureTech Health in August 2025. Lead program is deupirfenidone (LYT-100), a Phase 3-ready deuterated pirfenidone candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic and inflammatory lung conditions.

Company Info

Sector:Biotechnology / Respiratory

Headquarters:Boston, Massachusetts, USA

Founded:2025

Website:www.celeatx.com/

Funding Round:Series A (2025 spinout, $180M)

Total Funding:$180M

Funding & Investor Relations

Notable Investors

PureTech Health (parent)

Upcoming Milestones & Key Dates

2026 H2

Clinical

Pivotal Phase 3 trial initiation (IPF)

2027+

Clinical

Anticipated topline Phase 3 readout (IPF)

Clinical Development Pipeline

Deupirfenidone (LYT-100)

Target: Deuterated pirfenidone

Idiopathic Pulmonary Fibrosis (IPF)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Deupirfenidone (LYT-100)

Target: Deuterated pirfenidone

Other fibrotic conditions

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Deupirfenidone (LYT-100)

Target: Deuterated pirfenidone

Inflammatory lung conditions

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Lung-Focused Celea Secures $180M for Pivotal Test of Pulmonary Fibrosis Drug ↗

Celea Therapeutics raises $180M to fund a pivotal clinical trial of its lead idiopathic pulmonary fibrosis drug candidate. (Source: MedCity News, 2026-07-01)

Leadership Team

To be confirmed

Chief Executive Officer (Celea spinout lead)

Careers & Job Openings

See all open roles

All departments

Boston, MA

Apply Now →